Ocuphire Pharma (Nasdaq: OCUP) has announced the acquisition of Opus Genetics, a clinical-stage gene therapy company focused ...
Ocuphire Pharma ( (OCUP) ) just unveiled an update. Ocuphire Pharma has acquired Opus Genetics in an all-stock merger, ...
Canaccord lowered the firm’s price target on Ocuphire Pharma (OCUP) to $10 from $18 and keeps a Buy rating on the shares. The firm noted ...
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...
Ocuphire Pharma acquires Opus Genetics, expanding its IRD gene therapy pipeline. The renamed company, Opus Genetics, will trade under "IRD" by late024.
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
In 2022, Opus Genetics signed an agreement with National Resilience for developing and manufacturing AAV vector-based gene ...
In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stokholders of Opus Genetics. Ocuphire insiders ...
Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback